Literature DB >> 17663527

Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.

Jens-Uwe Kunstler1, Bhadrasetty Veerendra, Said D Figueroa, Gary L Sieckman, Tammy L Rold, Timothy J Hoffman, Charles J Smith, Hans-Jurgen Pietzsch.   

Abstract

Bombesin (BBN) peptide exhibits high selectivity and affinity for the gastrin-releasing peptide receptor (GRPr). The GRPr is overexpressed on many human cancer cell types, thus making BBN a potent delivery vehicle for radionuclide targeting. In this study, the biologically active minimal sequence BBN(7-14) was labeled using the novel Tc '4 + 1' mixed-ligand system, [Tc(NS3)(CN-R)], in which Tc(III) is coordinated by a monodentate isocyanide linker bearing the peptide and the tetradentate, tripodal chelator, 2,2',2''-nitrilotriethanethiol (NS3). BBN(7-14) was N-terminally modified with Gly-Gly-Gly, betaAla, and Ser-Ser-Ser spacer groups (X) and functionalized with 4-(isocyanomethyl)benzoic acid (L1) or 4-isocyanobutanoic acid (L2), resulting in a series of [M(NS3)(L-X-BBN(7-14))] conjugates (M = 99mTc, Re). The isocyanide ligand frameworks were introduced using novel bifunctional coupling agents. The spacer groups (X), the monodentate isocyanide units, and a tetradentate NS3 chelator bearing a pendant carboxylic acid (NS3COOH) were proposed as pharmacological modifiers. 99mTc-labeling was performed in a two-step procedure by first preparing 99mTc-EDTA/mannitol followed by reactions with the isocyanides and NS3 or NS3COOH ligand frameworks. The 99mTc complexes were obtained with a radiochemical yield of 30-80% depending on the amount of the isocyanide (20-100 nmol) used. These new conjugates were purified by reversed-phased high-performance liquid chromatography (RP-HPLC) to give a radiochemical purity of >or=95%. The 99mTc conjugates exhibited high in vitro stability (>90%, 24 h). Analogous nonradioactive Re conjugates were synthesized and characterized by electrospray ionization mass spectrometry (ESI-MS). RP-HPLC analyses of the Re conjugates indicated that they exhibited identical retention times to the corresponding 99mTc conjugates under identical HPLC conditions, demonstrating structural similarity between the two metalated species. The [Re(NS3)(L-X-BBN(7-14))] conjugates exhibited GRPr affinity in the nanomolar range as demonstrated by in vitro competitive binding assays using PC-3 human prostate cancer cells. In vitro internalization/externalization assays indicated that approximately 65% of [99mTc(NS3)(L2-betaAla-BBN(7-14))] conjugate was either surface-bound or internalized in PC-3 cells. Cell-associated activity for all other 99mTc conjugates was below 20%. Biodistribution studies of [99mTc(NS3)(L-betaAla-BBN(7-14))], L = L1 or L2, in normal, CF-1 mice showed minimal accumulation in normal pancreas (a tissue expressing the GRPr in high density in rodent models) and rapid hepatobiliary elimination. Introduction of a carboxyl group onto the NS3 ligand framework had only minimal effects to increase renal excretion. Activity distribution and accumulation was highly dominated by the relatively lipophilic '4 + 1' complex unit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17663527     DOI: 10.1021/bc700197m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  6 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Pyridyl-Cyclopentadiene Re(CO)(2) Complexes as a Compact Core Systems for SPECT Ligand Development.

Authors:  Nathan C Ackroyd; John A Katzenellenbogen
Journal:  Organometallics       Date:  2010-08-23       Impact factor: 3.876

3.  (18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor.

Authors:  Ying Li; Zhibo Liu; Curtis W Harwig; Maral Pourghiasian; Joseph Lau; Kuo-Shyan Lin; Paul Schaffer; Francois Benard; David M Perrin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

4.  68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients.

Authors:  Jingjing Zhang; Deling Li; Lixin Lang; Zhaohui Zhu; Ling Wang; Peilin Wu; Gang Niu; Fang Li; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2015-10-08       Impact factor: 10.057

5.  A bombesin-shepherdin radioconjugate designed for combined extra- and intracellular targeting.

Authors:  Christiane A Fischer; Sandra Vomstein; Thomas L Mindt
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-27

6.  Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with 99mTc and 177Lu as Potential Receptor Radiopharmaceuticals.

Authors:  Agnieszka Majkowska-Pilip; Przemysław Koźmiński; Anna Wawrzynowska; Tadeusz Budlewski; Bogusław Kostkiewicz; Ewa Gniazdowska
Journal:  Molecules       Date:  2018-10-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.